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Abstract
Instroduction—In patients with primary cutaneous melanoma, there is generally a delay 
between excisional biopsy of the primary tumor and sentinel-node biopsy. The objective of this 
study is to analyze the prognostic implications of this delay.
Patients and method—This was an observational, retrospective, cohort study in four tertiary 
referral hospitals. A total of 1963 patients were included. The factor of interest was the interval 
between the date of the excisional biopsy of the primary melanoma and the date of the sentinel-
node biopsy (delay time) in the prognosis. The primary outcome was melanoma-specific survival 
and disease-free survival.
Results—A delay time of 40 days or less (HR, 1.7; CI, 1.2 to 2.5) increased Breslow thickness 
(Breslow ≥2 mm, HR >3.7; CI 1.4 to 10.7), ulceration (HR 1.6; CI, 1.1 to 2.3), sentinel-node 
metastasis (HR, 2.9; CI, 1.9 to 4.2), and primary melanoma localized in the head or neck were 
independently associated with worse melanoma-specific survival (all P<0.03). The stratified 
analysis showed that the effect of delay time was at the expense of the patients with a negative 
sentinel-node biopsy and without regression.
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Conclusion—Early sentinel-node biopsy is associated with worse survival in patients with 
cutaneous melanoma.
Keywords
Melanoma; prognosis; sentinel lymph node; waiting list; skin surgery
Introduction
Sentinel lymph node is a standard staging procedure in melanoma management. Although its 
relevance in overall survival has not been clearly demonstrated so far, its value to stratify 
melanoma patients into prognostic groups is unquestionable[1].
There is, usually a delay between excision of the primary tumor and performance of 
sentinel-node biopsy, attributable to multiple factors, including surgical scheduling, 
preoperative assessment and planning, and sometimes, limited health care resources. The 
influence of this delay in prognosis remains unclear to date. Three decades ago, Sim et al[2] 
evaluated the therapeutic value of elective lymph node dissection and compared immediate 
lymphadenectomy versus delayed lymphadenectomy between 2 and 4 months bearing in 
mind the possible role of the regional lymph defensive system of the host against melanoma. 
They found no significant differences in survival but the arm of patients treated by 
immediate lymphadenectomy (n=54) showed a slight tendency to metastasize before with a 
worse prognosis (n=55). More recently, Parrett et al. evaluate the effect of time to sentinel-
node biopsy on sentinel-node involvement, recurrence, and mortality, and found no 
significant differences in survival on comparing a delay time of less than 40 days with one 
of 40 days or more[3]. They did, however, detect a trend towards higher melanoma-specific 
mortality in patients who underwent early sentinel-node biopsy (less than 40 days) and 
attributed this to a higher frequency of ulceration and thicker tumors in this group. They also 
admitted that their results were underpowered due to the relatively small number of patients 
evaluated (n=492).
This delay time has not been sufficiently studied regarding the prognosis of these patients.
The objective of this study was to further evaluate in a large series of patients the effect on 
survival of the delay between excision of a primary melanoma and performance of sentinel-
node biopsy.
Patients and Methods
We performed a multi-institutional retrospective observational study in which we selected 
all cases of primary cutaneous melanoma registered in databases at four hospitals: Hospital 
Universitario “Virgen de la Victoria” (HUVV) in Malaga, Spain; Instituto Valenciano de 
Oncología (IVO) in Valencia, Spain; Hospital Clínic Universitari de Barcelona (HCUB) in 
Barcelona, Spain; and Gustave-Roussy (GR) in Villejuif-Paris, France. It is noteworthy that 
all databases included patients’ data in a prospective way. Relevant ethical standards 
regarding the use of databases were applied in all cases.
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The study included patients with a single primary melanoma (clinical stage I or II) who had 
undergone sentinel-node biopsy within 120 days of excision of the primary tumor and who 
were still alive at the end of this period (n=1977). Patients who developed a recurrence 
during this time (n=14) were excluded. The final number of patients evaluated was 1963.
The inclusion dates and number of patients evaluated at each of the hospitals were as 
follows: October 1, 2001 to December 31, 2012 at the HUVV (n=189); January 1, 2000 to 
December 31, 2012 at the IVO (n=415); February 1, 1997 to December 31, 2012 at the 
HCUB (n=847); and January 1, 2003 to December 31, 2012 at GR (n=512). The dates 
corresponded to the periods during which the patient data had been prospectively recorded. 
The study was approved by local ethic committee.
The main variable was the interval between the date of the excisional biopsy of the primary 
melanoma and the date of the sentinel-node biopsy. This interval, defined as delay time, was 
used as continuous variable and also categorized using the minimum p-value approach,[4] 
which consisted of performing multiple log-rank tests to compare survival curves and 
determine the optimal cutoff point for separating the patients into two groups. We analyzed 
intervals of 10 days, from day 10 up to day 60. The optimal cutoff was established at 40 
days (40 days or less vs. more than 40 days) based on the minimum p-value obtained. This 
value was contrasted with a recursive partitioning method for categorize variable 
(Classification and regression tree)[5] and the result was 40.5 days which was rounded to 40 
days.
The following clinical covariates were also included: age (both, continuous and 
dichotomized ≤65 vs. >65 yrs.), sex, and anatomical site (head and neck, trunk, extremities, 
and hands/feet).
We also analyzed the following histologic features: Breslow thickness (continuous and 
categorized in four groups: ≤1.00, 1.01–2.00, 2.01–4.00, or >4.00 mm) [6], ulceration 
(present vs. absent), regression (present vs. absent), and sentinel-node status (positive vs. 
negative).
Pathologic examination of the sentinel lymph nodes at each hospital was performed using 
standard procedures that have previously been described[7, 8] The HCUB has been applying 
the Minitub protocol (EORTC 1208: Minitub registration study) since 2011.
Associations between delay time and other variables were investigated using chi-square 
tests.
The main outcome was disease-free survival and melanoma-specific survival. Survival was 
defined as time from baseline, that is, the time from the date of the excision of the primary 
melanoma plus 120 days, to the date of the first recurrence or death (events for disease-free 
and melanoma-specific survival, respectively) or to the date of the last follow-up, whichever 
occurred first. Disease-free and melanoma-specific survival curves for delay time were 
generated using the Kaplan-Meier method. The log-rank test was used to perform univariate 
analyses. Multivariate analyses were performed with Cox proportional hazard models. The 
assumption of proportionality was evaluated graphically using "log-log" plots in the two-
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sample comparison case. An analysis of missing values was also performed. These values 
were imputed using a complete-case (multiple imputation) model[9] for which we ran five 
iterations and combined estimates and standard errors using Rubin’s rules. Prior to 
developing the model, we tested if the data were randomly missing using the missing values 
add-on module in the SPSS statistical package. A P value of less than 0.05 was considered 
to indicate statistical significant. SPSS software version 20.0 (SPSS) was used for all 
statistical analyses. Kaplan-Meier curves were drawn using SAS software version 9.3, Cary, 
North Carolina, USA.
Vital status of patients lost to follow-up was systematically reviewed through the respective 
National Mortality Registry.
Results
We evaluated 1963 patients with a single primary melanoma who had undergone sentinel-
node biopsy. There were 967 women (49.3%) and 996 men (50.7%), with a median age of 
53 years (interquartile range, 41 to 65) (Table 1).
Patients with a delay time of 40 days or less had a higher frequency of ulceration (38.6% vs. 
32.1%, P=0.014) and melanoma located on the hands and feet and a lower frequency of 
melanoma on the extremities (P<0.001). No significant association was found for age, sex, 
stratified o continuous Breslow thickness, regression, or a higher frequency of sentinel-node 
involvement.
After a median follow-up of 46 months (interquartile range, 20–77), 209 (10.6%) patients 
had died and 368 (18,7%) had developed a recurrence (uncensored patients for melanoma-
specific survival and disease-free survival, respectively).
We identified 594 patients (30.2%) lost to follow-up until 31 December 2012. Vital status 
was systematically reviewed in all cases and it was ascertained that 5 patients (1%) had died. 
A sensitivity analysis was performed on the reviewed data and the results were similar (data 
not shown).
A delay time of more than 40 days was associated with better 5-year disease-free survival 
(80.1% vs. 73.8%, P<0.0839) (Figure 1A) and better 5-year melanoma-specific survival 
(89.5% vs. 82%; P=0.0002) (Figure 1B).
On analyzing cases of regional lymph node involvement during follow-up, we also found no 
differences between the rate of false-negative sentinel-node in the two groups (21,3% vs. 
18.1%). False-negative sentinel-node was calculated as the amount of false negative results 
divided by the amount of false-negative + true positives as suggested van Akkooi et al.[10]
There was no evidence of difference in the type of recurrence in both groups (Table 1).
The main prognostic factor for disease-free and melanoma-specific survival in the overall 
group was sentinel-node positivity. Five-year disease-free survival was 85.5% for patients 
with a negative biopsy and 56% for those with a positive biopsy. The corresponding rates 
for 5-year melanoma-specific survival were 92.4% and 71.4% respectively. The stratified 
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analysis by sentinel-node status showed better disease-free and melanoma-specific survival 
for patients with a delay time of 40 days or more in both the node-positive and node-
negative groups (Figures 1C–1F). Although there was a statistical significance only in the 
negative sentinel lymph node group. In this group, a delay time of 40 days or less was 
associated with melanomas located in hands and feet. The rest of variables were quite 
homogenous (Table 4).
A delay time of 40 days or less or as continuous variable retained its statistical significance 
after adjusting for all co-variates in the multivariate analysis for melanoma-specific survival 
in the whole population of patients (Table 3.). In these models, sentinel-node involvement, 
Breslow thickness, sex, ulceration, and anatomical site were all also significant prognostic 
factors for both disease-free and melanoma-specific survival. Delay time did not retain its 
significance as an independent prognostic factor for disease-free survival. Multivariate 
analysis stratifying by sentinel-node metastasis status showed that delay time was only 
significant for patients with a negative sentinel-node biopsy (Table 5).
We also performed stratified analysis based on the presence or absence of regression, 
patients showed a lower survival rate in the group of less than 40 days only in the case of the 
absence of regression. In the presence of histologic regression, a worsening of survival did 
not exist for patients with a shorter delay to 40 days (Figure 2). In a multivariate analysis the 
delay time retained its statistical significance only for cases without regression (Table 6).
Discussion
In this study of 1963 patients from four leading hospitals in Spain and France, we have 
shown for the first time that the interval between excision of a primary cutaneous melanoma 
and performance of sentinel-node biopsy has prognostic significance, with worse melanoma-
specific survival observed in patients who undergo early biopsy, specifically, in those with a 
negative sentinel-node biopsy and absence of regression in the primary tumor.
Ulceration and Breslow thickness were associated with a worse prognosis in our patients, 
particularly in the absence of nodal involvement, as it has previously been shown[11–14]. 
Location on head and neck and, to a lesser extent, on acral sites was associated with worse 
MSS and DFS, findings that are consistent with previous reports[11, 15].
To our knowledge, only two studies to date, published by Parrett et al.,[3] and at the same 
time, in this volume, the study of Oude Ophuis et al.[16], have studied the impact of the 
timing of sentinel-node biopsy on survival in melanoma patients. In Parrett’s study, 
surprisingly, they observed an increased frequency of recurrence and melanoma-specific 
mortality in patients with a delay time of less than 40 days. The authors attributed the higher 
mortality and recurrence rates observed in the early group to the fact that sentinel-node 
biopsy tends to performed sooner in patients with thicker or ulcerated melanomas.
In a similar way, Oude Ophius et al., have analyzed the same topic on a database of the 
EORTC Melanoma Group exclusively in patients with a positive SLN. Observing that, the 
timing of sentinel-node biopsy for any interval is not an independent prognostic factor in 
this group of patients[16].
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In our series, thicker and/or ulcerated melanomas were also overrepresented in the ‘early 
group’. In addition, we noticed a shorter delay for patients with melanomas located on the 
hands and feet, possibly because sentinel-node biopsy is sometimes performed at the same 
time as excision of the primary tumor in large or acral melanomas which are often surgically 
more complex.[17] Our study is in agreement with the results of Oude Ophius et al., since 
the time to sentinel-node biopsy did not prove to be an independent prognostic factor in the 
group of patients with a positive SLN. However, time to sentinel-node biopsy retained its 
significance as an independent prognostic factor for MSS after adjusting for all these 
variables in the multivariate analysis for patients with a negative SLN.
There are no studies to our knowledge, apart from that by Parrett et al.[3], that offers a 
possible explanation for the biological plausibility of our findings. Sentinel-node biopsy is 
predicated on the assumption that melanoma spreads from the primary tumor to the sentinel 
lymph node before reaching the other nodes in the regional basin.[18]
The sentinel node is the first organ in the lymphatic system that acts as a barrier to tumor 
spread; accordingly it is also the first structure encountered by tumor antigens traveling 
through the lymph system from the primary lesion.[19]
The immunogenic capacity of melanoma is well established and forms the basis of various 
immune-based therapies targeting different immune pathways.[20]
Induction of a specific antitumor T-cell response depends on the priming of specific naïve T 
cells by dendritic cells in the draining lymph nodes[21, 22]. When a specific antigen is 
presented by dendritic cells, the naïve T cells are activated.[23] Priming of helper and 
cytotoxic anti-tumor T cells seems to take place in the SN and potentially causes an 
antitumor T-cell response in melanoma.
The immunosuppressive effect of melanoma, however, has been well documented, in 
particular in draining lymph nodes where several mechanisms impairing the activation of 
regional immunity have been described.[24] This immunosuppression occurs even in the 
absence of sentinel-node involvement[25], suggesting that it may be partly mediated by the 
release of different cytokines from the primary tumor.[26–29]
The above-described immunosuppressive state could be reversible following excision of the 
primary melanoma.[28] In this sense, it has been observed a correlation in the maturation of 
dendritic cell with respect to a prolonged delay time between the excision of primary tumor 
and the sentinel lymph node biopsy[30].
Considering what is known about the immunobiology of melanoma and based on the 
findings of our study, it could be hypothesized that the immunosuppressive sentinel-node 
microenvironment would disappear following excision of the primary tumor, allowing the 
induction of an efficient antitumor-specific immune response over the following weeks. In 
this scenario, early removal of the sentinel node would prevent this response and be 
detrimental to patients. Thus, it is possible that our apparently paradoxical results could be 
explained by the fact that, at the early stages (melanoma stages I and II), a short time 
interval between primary excision and sentinel-node biopsy could be deleterious for 
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mounting an efficient antitumor immune response. Accordingly, in the setting of the 
presence of regression in primary melanoma, which is supposed to be a sign of immune 
response against tumor, it was not possible to observe an effect in delay time.
Our study has certain limitations. Given that our conclusions are based on the retrospective 
analysis of prospectively collected data, the possibility of bias must be considered. A high 
proportion of patients were lost-to follow-up. To minimize the effect of this weakness, we 
systematically reviewed the status of these patients using National Mortality Registries. We 
also did not include mitotic rate in the analyses, since there was not a systematic and 
centralized review of the melanoma histologies, the criteria used varied both between 
centers. It is possible that tumors with higher proliferative activity and faster clinical growth 
may have been candidates for earlier sentinel-node biopsy. However, to minimize this risk, 
we performed the necessary adjustments in the multivariate model.
Finally, it is noteworthy that the risk of selection or treatment bias is also limited by the fact 
that we studied a large group of patients and analyzed prospectively collected data that had 
not been collected for the purpose of the present study.
In conclusion, our results raise important questions and the implication that early sentinel-
node biopsy reduces melanoma-specific survival in patients, needs to be further and 
prospectively explored. But, what is clear is that a delay in the procedure did not worse the 
prognosis in any case. Future studies will also need to determine the underlying etiologic 
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Table 1
Clinical and Pathological Characteristics of the Study Population (n=1963)*.
Delay Time
Variable ≤40 days >40 days Total Patients P Value
Age (yr) N=625 N=1320 N=1945
≤65 446 (71.4) 975 (73.9) 1421 (72.1) 0.245
>65 179(28.6) 345 (26.1) 524 (26.9)
Mean (year; SD) 54.2 (16.2) 54.6 (15.7) 0.6
Sex N=631 N=1324 N=1955
Male 317 (50.2) 646 (48.8) 963(49.3) 0.55
Female 314 (49.8) 678 (51.2) 992 (50.7)
Breslow thickness (mm) N=630 N=1315 N=1945
<1 102 (16.2) 249 (18.9) 351 (18) 0.132
1.01–2 254 (40.3) 535 (40.7) 789(40.6)
2.01–4 183 (29) 323 (24.6) 506 (26)
>4 91 (14.4) 208 (15.8) 299 (15.4)
Mean (mm; SD) 2.6 (2.4) 2.6 (2.8) 0.7
Ulceration N=461 N=1096 N=1557
Present 178 (38.6) 352 (32.1) 530 (34) 0.014
Absent 273 (61.4) 784 (67.9) 1158 (66)
Regression N=593 N=1219 N=1812 0.64
Present 117 (19.7) 252 (20.7) 369 (20.4)
Absent 476 (80.3) 967 (79.3) 1443 (79.6)
Sentinel-node status N=633 N=1329 N=1962
Positive 163 (25.8) 301 (22.6) 464 (23.6) 0.131
Negative 470 (74.2) 1028 (77.4) 1498 (76.4)
Anatomical site N=634 N=1329 N=1963
Head and neck 63 (9.9) 188 (14.1) 251 (12.8) <0.001
Trunk 221 (34.9) 559 (42.1) 780 (39.7)
Extremities 240 (37.9) 474 (35.7) 714 (36.4)
Hands/feet 110 (17.4) 108 (8.1) 218 (11.1)
Time of follow-up (months) 51 (1–192) 45 (1–170)
Recurrence N=586 N=1274 N=1860
Yes 135 (23) 204 (16) 339 (18.2) <0.001
No 451 (77) 1070 (84) 1521 (81.8)
Death N=586 N=1275 N=1861
Yes 93 (16.9) 95 (7.8) 188 (10.5) <0.001
No 493 (84.1) 1180 (92.5) 1673 (89.9)
Type of recurrence N=82 N=134
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Delay Time
Variable ≤40 days >40 days Total Patients P Value
Local 4 (4.9) 9 (6.7) 13 (6) 0.23
Satellitosis/In-transit 12 (14.6) 34 (25.4) 21 (19.6)
Regional lymph node 25 (30.5) 32 (23.9) 57 (26.4)
Systemic 41 (50) 59 (44) 100 (46.3)
*
Data shown as number (%) of patients unless otherwise indicated. SD: Standard deviation.
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Table 2
Univariate Analysis of Prognostic Factors for Disease-Free and Melanoma-Specific Survival in Patients Who 














































































































HVV: Hospital Virgen de la Victoria; IVO: Instituto Valenciano de Oncología; HCUB: Hospital ClínicUniversitari de Barcelona; GRC: Gustave-
Roussy Center.
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Table 3
Multivariate Analysis of Prognostic Factors for Disease-Free and Melanoma-Specific Survival in Patients 
Who Underwent Sentinel-Node Biospy (n=1963).
Disease-free Survival
MODEL 1





>4.00 <0.001 8 (3–21.4)
Ulceration
Present 0.01 1.7 (1.2–2.5)
Absent 1 (Reference)
Localization
Head and Neck 1 (Reference)
Trunk 0.011 0.5(0.3–0.8)
Extremities <0.001 0.3(0.2–0.6)
Hands/feet 0.35 0.7 (0.4–1.3)
Sentinel lymph node status





Male 0.003 1.4 (1.1–1.8)
Age 0.001 1.01(1.05–1.02)
Breslow Thickness (mm) <0.001 5.2 (3.6–7.5)
Ulceration
Present 0.01 1.4 (1.1–1.8)
Absent 1(Reference)
Sentinel lymph node status
Positive <0.001 2.6 (2.1–3.2)
Negative 1 (Reference)
Localization
Head and Neck 1 (Reference)
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Trunk 0.001 0.6 (0.4–0.8)
Extremities <0.001 0.5 (0.4–0.6)
Hands/feet 0.06 0.7 (0.5– 1.01)
Melanoma-Specific Survival
MODEL 1
Time to sentinel-node biopsy 0.007 1.7 (1.2–2.5)





2.01–4.00 0.007 3.7 (1.4–10.7)
>4.00 0.003 4.5(1.7–12.1)
Ulceration
Present 0.029 1.6 (1.1–2.3)
Absent 1 (Reference)
Localization
Head and Neck 1 (Reference)
Trunk <0.001 0.4 (0.2–0.6)
Extremities <0.001 0.4 (0.2–0.6)
Hands/feet 0.018 0.5 (0.2–0.9)
Sentinel lymph node status





Male 0.02 1.4 (1.1–2)
Age (per year) 0.03 1.01 (1.001–1.02)
Brewlow thickness <0.001 3.4 (2.1–5.8)
Localization
Head and Neck 1 (Reference)
Trunk 0.002 0.5 (0.3-.8)
Extremities 0.006 0.6 (0.4–0.8)
Hands/feet … …
Sentinel lymph node status
Positive
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Negative <0.001 2.9 (2.1–3.9)
Time to sentinel-lymph biopsy 0.01 0.6 (0.4–0.9)
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Table 4
Clinical and pathological characteristics of patients with negative sentinel lymph node biopsy (n=1497).
Delay Time
Variable ≤40 days >40 days Total Patients P Value
Age (years) N=464 N=1019 N=1483
≤65 325 (70) 753 (73.9) 1078 (72.7) 0.12
>65 139 (30) 266 (26.1) 405 (27.3)
Mean (years; SD) 54.3 (16.9) 54.2 (15.2) 0.9
Sex N=468 N=1022 N=1490
Male 225 (48.1) 513 (50.2) 738 (49.5) 0.44
Female 243 (51.9) 509 (49.8) 752 (50.5)
Breslow thickness (mm) N=468 N=1015 N=1483
<1 98 (20.9) 233 (23) 331 (22.3) 0.15
1.01–2 220 (47) 444 (43.7) 664 (44.8)
2.01–4 109 (23.3) 215 (21.2) 324 (21.8)
>4 41 (8.8) 123 (12.1) 164 (11.1)
Mean (mm; SD) 2.1 (1.6) 2.3 (2.8) 0.1
Ulceration N=335 N=835 N=1170
Present 102 (30.4) 229 (27.4) 331 (28.3) 0.3
Absent 233 (69.6) 606 (76.6) 839 (71.7)
Regression N=444 N=944 N=1388 0.94
Present 99 (22.3) 212 (22.5) 311 (22.2)
Absent 345 (77.7) 732 (77.5) 1077 (77.6)
Anatomical site N=471 N=1026 N=1497
Head and neck 45 (9.6) 171 (16.7) 216 (14.4) <0.001
Trunk 161 (34.2) 395 (38.5) 556 (37.1)
Extremities 189 (40.1) 383 (37.3) 572 (38.2)
Hands/feet 76 (16.1) 77 (7.5) 153 (10.2)
Time of follow-up (months) 53 (1–192) 45 (1–188)
Recurrence N=433 N=985 N=1418
Yes 66 (15.2) 113 (11.5) 179 (12.6) 0.049
No 367 (84.8) 872(88.5) 985 (69.5)
Death N=433 N=986 N=1419
Yes 46 (10.6) 45 (4.6) 188 (10.5) <0.001
No 387 (89.4) 941 (95.4) 1328 (93.6)
Type of recurrence N=38 N=69
Local 3 (7.9) 7 (10.1) 10 (9.3) 0.7
Satellitosis/In-transit 6 (15.8) 15 (21.7) 21 (19.6)
Regional lymph node 11 (28.9) 14 (20.3) 25 (23.4)
Systemic 18 (47.4) 33 (47.8) 51 (47.7)
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*
Data shown as number (%) of patients unless otherwise indicated. SD: Standard deviation.
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